INTRODUCTION AND OBJECTIVES:
Vestibulectomy is a surgical procedure performed for the treatment of superficial dyspareunia caused by vestibulodynia and is typically done when conservative management has failed. Surgery is performed in an outpatient setting and results in the removal of the entire vulvar vestibule, including all underlying endodermally derived tissue, and advancing a vaginal flap onto the perineum. Relatively few vestibulodynia patients ultimately require surgical intervention, and as a result, data on their experiences and outcomes is limited. We set out to elucidate the post-operative experiences of patients who have undergone this procedure in single center.
METHODS: We conducted a retrospective chart review of vestibulodynia and dyspareunia patients in a private practice in Washington, DC focused on Women's Health and Sexual Medicine. Additionally, an internet-based survey was sent to patients who underwent vestibulectomy to assess post-operative experience and satisfaction.
RESULTS: From 2013-2017 there were 676 new patients with vulvodynia. Of those, 39 underwent vestibulectomy surgery (5.8%). Age at time of surgery averaged 28 (ranging 18-50). The average length of time from diagnosis to surgery was 520 days. An Internet survey was sent to all 39 surgical patients with 29 responses (74.3%). 26 of 29 (89.7%) reported being able to have comfortable intercourse after surgery (13 reporting this was not 100% of the time), with the remaining 3 patients reporting they had not yet attempted penetration. Time to comfortable intercourse averaged 4-6 months in more than half of responders. When asked "if you could go back in time, knowing what you now know about the effects of your vestibulectomy, would you choose to have this surgery?" 100% responded "yes". Additionally, patients reported improvements in desire (n[13), arousal (n[8), orgasm (n[6), and enjoyment (n[19). The average recovery time (back to work/ school) was reported as 5 weeks (ranging 2 weeks-3 months). METHODS: An observational, prospective study was conducted in 2 Italian centers. Fifty sexually active, iOAB women were enrolled. At baseline, all patients underwent urogynecologic assessment (physical examination, 3-day voiding diary and uroflowmetry with post-void residual volume, PVR, measurement). Patients completed the Female Sexual Function Index (FSFI) questionnaire, the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and VAS to score the impact of urinary symptoms on Quality of Life (QoL; 0[ worse; 10[ best) . Patients started assuming Mirabegron 50 mg once daily. Clinical evaluation and questionnaires were repeated again at 12 wks follow-up. Side effects were also noted.
RESULTS: All patients completed the study. Mean AE SD age was 49.3 AE 11.3 yrs. At baseline, all patients presented with increased day-time and night-time urinary frequencies and urgency, and 47/50 (94%) had urgency urinary incontinence. At the 12 wks follow-up 28/ 50 patients (56%) became completely continent and symptoms improved in all cases. No increase in PVR was detected. At baseline 49/50 patients (98%) presented with FSD. At 12 wks follow-up, 42/50 patients (84%) reported improvements in FSFI Total Score and 16 patients (32%) presented with no FSD. (Table) Mean AE SD ICIQ-SF score significantly increased from 17.1 AE 5 (pathologic value) to 7.9 AE 4.8 (normal value; p< 0.0001). Most importantly, the mean AE SD VAS score significantly increased from 3.9 AE 1.2 to 6.9 AE 1.2 (p< 0.0001). We did not observe any intolerable side effects.
CONCLUSIONS: The observed ability of Mirabegron in improving FSD in our patients with iOAB, can be explained by the overall amelioration in OAB symptoms. Indeed, it can be also hypothesized that, like in males, Mirabegron improved SD in our patients by inducing a cGMP dependent vasorelaxation of female genitalia. This could explain the significant improvement observed particularly in arousal and orgasm domains of FSFI. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e381
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